Skip to content
Screener

Cogent Biosciences, Inc. COGT Q2 2026 earnings

Reported August 10, 2026 · Before market open

EPS-$0.52Beat by $0.03
Revenue estimate$1.0K
EPS estimate-$0.55

Next report

Nov 6, 2026 (in a month)
Revenue estimate$750.0K
EPS estimate-$0.57

Financials

Q2 2026

Income statement

See full
Operating income-$102.6M-35.8%
Net income-$96.4M-31.1%
EPS (diluted)-$0.52+1.9%

Balance sheet

See full
Cash & equivalents$181.2M+42.0%
Total debt$20.8M-65.7%
Total equity$532.4M+243%
Total assets$834.5M+204%

Cash flow

See full
Operating cash flow-$77.3M-41.7%
CapEx$370.0K+182%
Free cash flow-$77.6M-42.0%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$5.48B+166%
Enterprise value$5.32B+167%

Returns & leverage

See full
Return on equity-109.7%+2.3pp
Debt / equity0×-0.4×
Current ratio13.6×+9.4×

FAQ

When did Cogent Biosciences, Inc. report Q2 2026 earnings?
Cogent Biosciences, Inc. (COGT) reported Q2 2026 earnings on August 10, 2026 before market open.
What were Cogent Biosciences, Inc.'s Q2 2026 revenue and EPS?
Cogent Biosciences, Inc. reported eps of $-0.52 for Q2 2026.
Did Cogent Biosciences, Inc. beat estimates in Q2 2026?
EPS beat the consensus estimate of $-0.55 by $0.03.
How did Cogent Biosciences, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 1.9% from $-0.53.
Where can I find Cogent Biosciences, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-341315) and the 10-Q periodic report (0001193125-26-342393) directly on SEC EDGAR. The filing index links above go to sec.gov.